Business Roundtable
From the Hill to the Street - Examining Policy Issues in Biotech
Monday, February 11, 2008
9:30 AM
Park Avenue Suite Center/North
Tracking and predicting how policy changes will affect the marketplace is a crucial task for biotech companies. Public perception of drug safety, the lack of a regulatory pathway for follow-on biologics and recent legistlation to reauthorize PDUFA and reform the FDA are all transformative issues. How does policy affect the marketplace? What kind of action can we expect to see from Washington this year? This roundtable will review current regulatory issues in Congress and discuss how a wise policy agenda can ensure Street support for biotech.
Moderators
- Alan Eisenberg; Executive Vice-President, Emerging Companies and Business Development, Biotechnology Industry Organization
Panelists
- John Swen; Executive Director, US Science Policy and Public Affairs, Pfizer Global Research
- Nick Littlefield; Partner and Co-Chair, Government Strategies Group, Foley Hoag LLP
- J. Donald deBethizy, Ph.D.; President and CEO, Targacept, Inc
- Hany Awadalla; Managing Director, Collins Stewart